FDA Approves Pimicotinib for Symptomatic TGCT
Summary
With the highest objective response rate in a phase 3 trial, Serono says its CSF-1R inhibitor is a potential 'best-in-class.'
Description from Medscape.
Who is covering this
-
FDA Approves Pimicotinib for Symptomatic TGCT
With the highest objective response rate in a phase 3 trial, Serono says its CSF-1R inhibitor is a potential 'best-in-class.'
Related stories
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
29 sourcesvia BBC NewsTruth score 9111
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
7 sourcesvia The HinduTruth score 731
Blood pressure medication recalled nationwide
4 sourcesvia USA TODAYTruth score 671
Trump administration says biggest changes coming to infant formula in nearly 30 years
2 sourcesvia ABC News (US)Truth score 533
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
3 sourcesvia Chicago Sun-TimesTruth score 59
Patanjali ghee among Rs 9 crore food stock seized in Maharashtra FDA crackdown
3 sourcesvia India TodayTruth score 54
Comments
Comments need JavaScript.